<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434135</url>
  </required_header>
  <id_info>
    <org_study_id>SICOG trial 0506</org_study_id>
    <nct_id>NCT00434135</nct_id>
  </id_info>
  <brief_title>Alimta and Gemcitabine in Non-Small Cell Lung Cancer</brief_title>
  <acronym>ANGEL</acronym>
  <official_title>A Phase II Randomized Trial Assessing the Combination of Gemcitabine and Pemetrexed in the First Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Italy Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Italy Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta
      (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of
      a randomized trial, and (2) to compare the GA with the paclitaxel plus gemcitabine (PG
      regimen) in terms of toxicity and QoL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stage IIIB or IV non-small cell lung cancer will be randomly allocated to
      receive: (a)PG regimen: paclitaxel 120 mg/sqm followed by gemcitabine 1,000 mg/sqm i.v. on
      days 1 &amp; 8 q 3 weeks; (b)GA regimen: gemcitabine 1,250 mg/sqm i.v. on day 1 (plus folinic
      acid 350 μg daily orally and vitamin B12 1,000 μg i.m. q 9 weeks), pemetrexed (Alimta®) 500
      mg/sqm i.v. on day 8 followed by gemcitabine 1,250 mg/sqm, q 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of patients treated with the gemcitabine plus Alimta regimen</measure>
    <time_frame>after 3 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of patients treated with gemcitabine plus Alimta regimen</measure>
    <time_frame>at the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients treated with gemcitabine plus Alimta regimen</measure>
    <time_frame>after 3 cyces</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB or IV</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine plus pemetrexed, paclitaxel plus gemcitabine</intervention_name>
    <description>gemcitabine 1,250 mg/sqm days 1&amp;8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&amp;8</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed locally advanced (stage IIIB)
             or metastatic (stage IV) NSCLC

          2. No previous adjuvant or palliative chemotherapy

          3. No previous radiotherapy

          4. Presence of at least one unidimensionally measurable lesion (Appendix 2)

          5. ECOG performance status of 0 or 1 (Appendix 3)

          6. Charlson score ≤ 2 (Appendix 4)

          7. Adequate bone marrow function (absolute neutrophil count ≥ 2 x 109/L, platelet count ≥
             100 x 109/L, and hemoglobin level ≥ 100 g/L), and adequate liver function (bilirubin
             level &lt; two times the upper limit of normal, AST and/or ALT &lt; three times the upper
             limit of normal, prothrombin time &lt; 1.5 times control), and creatinine clearance ≥ 60
             ml/min.

          8. Absence of symptomatic CNS metastases (patients with cerebral metastases treated with
             brain irradiation may be included), severe cardiac arrhythmia or heart failure, second
             or third degree heart block or acute myocardial infarction within 4 months prior to
             study entry.

          9. No major surgery or pleurodesis within 14 days prior to enrollment.

         10. Life expectancy of at least 12 weeks.

         11. No previous or concurrent malignancy, except inactive non-melanoma skin cancer, in
             situ carcinoma of the cervix, or other cancer if the patient has been disease-free for
             more than 5 years.

         12. Written informed consent

        Exclusion Criteria:

          1. Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, serious cardiac arrhythmia requiring
             medication, hepatic, renal or metabolic disease).

          2. Patients with clinically significant effusions.

          3. Any other malignancies within 5 years that could affect therapy evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquale Comella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Tumor Institute, Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Tumor Institute</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pasquale Comella MD</name_title>
    <organization>Southern Italy Cooperative Oncology Group</organization>
  </responsible_party>
  <keyword>gemcitabine</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

